We are live on
!
Find out more
State Street SPDR S&P Pharmaceuticals ETF
XPH
XPH
81 hedge funds and large institutions have $127M invested in State Street SPDR S&P Pharmaceuticals ETF in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
1% more funds holding
Funds holding: 80 → 81 (+1)
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
3.58% less ownership
Funds ownership: 51.23% → 47.65% (-3.6%)
11% less capital invested
Capital invested by funds: $143M → $127M (-$16.2M)
Holders
81
Holders Change
+1
Holders Change %
+1.25%
% of All Funds
1.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
22
Reduced
22
Closed
5
Calls
$225K
Puts
–
Net Calls
+$225K
Net Calls Change
-$2.06M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$1.5M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.19M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$777K |
| 4 |
LPL Financial
San Diego,
California
|
+$335K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$323K |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$11.4M |
| 2 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$1.54M |
| 3 |
CF
Centaurus Financial
Anaheim,
California
|
-$1.17M |
| 4 |
Morgan Stanley
New York
|
-$910K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$780K |
